VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO GI 2023 | Practical considerations for genomic testing in colorectal cancer

Stacey Cohen, MD, Fred Hutchinson Cancer Center, Seattle, WA, comments on how genomic testing for molecular aberrations can influence treatment approaches in colorectal cancer. Liquid biopsies enable monitoring of multiple ctDNA mutations of varying frequencies, which can ultimately inform clinicians when a treatment regimen should be changed. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter